US LNG exports surge but will buyers in China turn up?
On Monday, Cantor Fitzgerald analysts reaffirmed an Overweight rating for Elutia stock, maintaining a price target of $7.00. Currently trading at $1.80, the stock shows significant upside potential, with analysts’ consensus targets ranging from $7.00 to $8.00, according to InvestingPro data. This decision follows Elutia’s announcement of a peer-reviewed article published in Dissolution Technologies, which introduces a validated method for measuring antibiotic release from a biologic envelope.
The new method, as detailed in the publication, replicates in vitro elution in 30 hours. This approach is expected to support the development of Elutia’s EluPro portfolio by offering a faster and more cost-effective solution.
According to the company, the innovative method is a significant advancement in the field, potentially aiding in the more efficient development of their product line.
Elutia, listed on NASDAQ under the ticker ELUT, continues to pursue advancements in biotechnology, with this latest publication marking a step forward in their research efforts.
In other recent news, Elutia Inc. reported its first-quarter 2025 earnings, exceeding analysts’ expectations with an earnings per share (EPS) of -0.21, beating the forecasted -0.24. However, the company’s revenue of $6.03 million fell short of the anticipated $6.8 million. The BioEnvelope division, a focal point for Elutia, achieved a 31% year-over-year growth, driven by the EleuPro product, which saw an 84% revenue increase from the previous quarter. Elutia’s cash position was bolstered by a $15 million direct offering in February, resulting in a total of $17.4 million. The company is also exploring strategic alternatives for its Sientra (OTC:SIENQ) contract while targeting $200 million in potential U.S. revenue from the EleuPro product. Analysts from firms like Lake Street Capital have noted the rapid adoption of EleuPro, with over 52 hospitals onboarded through a partnership with Boston Scientific (NYSE:BSX). Elutia aims to expand its EleuPro product to 1,000 hospitals and forecasts future revenue growth, with projections of $7.8 million for Q2 2025 and $8.9 million for Q3 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.